 Lantern Pharma Inc NASDAQ: LTRN has announced new preclinical data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. These data demonstrated that the drug candidate, LP-184, exhibited significant and rapid pancreatic tumor shrinkage, by over 90, in in-vivo mouse models in 8 weeks. 